The impact of initial antidiabetic agent and use of monitoring agents on prescription costs in newly treated type 2 diabetes: A retrospective cohort analysis

Diabetes Research and Clinical Practice
R T GrimesM C Henman

Abstract

To measure the costs associated with the use of antidiabetic agents, monitoring materials and cardiovascular disease (CVD) agents in the management of newly treated type 2 diabetes, and to investigate the factors associated with these costs. A population-based retrospective cohort study was conducted using the Irish national pharmacy claims database. Newly treated patients were identified for 2012 and followed for one year post treatment initiation. Factors associated with costs were assessed using a generalised linear model with gamma family and log-link function. Cost ratios (CR) and 95% CIs were used to determine the contributors of prescription costs. Adjusted odd ratios (OR) and 95% CIs were used to investigate factors associated with high frequency self-monitoring of blood glucose (SMBG). Mean prescription costs for the 12,941 subjects was €871, while total costs were €11 million. CVD agents accounted for 58% of total costs; 22% of costs were for SMBG; antidiabetic agents accounted for 17% of costs. SMBG resulted in costs that were 80% higher than those without, CR 1.80 (95% CI 1.76-1.84). No significant differences were observed between initiation on metformin or sulphonylureas and high frequency SMBG (OR 1.01 95% CI 0.9...Continue Reading

References

Oct 25, 2003·BMJ : British Medical Journal·Jonathan M LordRobert J Norman
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Jan 17, 2009·Health Services Research·Amanda A HoneycuttEric A Finkelstein
Apr 3, 2009·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·UNKNOWN Health Care Professional Association Writing Group
Dec 17, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·B GuthrieA D Morris
Mar 17, 2010·Health Technology Assessment : HTA·C ClarUNKNOWN Aberdeen Health Technology Assessment Group
Nov 9, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jean-Pierre GrégoireJocelyne Moisan
Mar 29, 2011·Pharmacoepidemiology and Drug Safety·Egbert J F LambertsMarcel L Bouvy
May 25, 2011·Diabetologia·L GovanUNKNOWN Scottish Diabetes Research Network Epidemiology Group
Feb 22, 2012·The American Journal of Medicine·Nihar R DesaiNiteesh K Choudhry
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Nov 5, 2013·The Canadian Journal of Cardiology·Line GuénetteJocelyne Moisan
Dec 19, 2014·British Journal of Clinical Pharmacology·Ronan T GrimesMartin C Henman
Apr 1, 2015·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·John RobsonKambiz Boomla

❮ Previous
Next ❯

Citations

Aug 19, 2017·European Journal of Clinical Pharmacology·Sarah-Jo SinnottCaitriona Cahir
Jul 23, 2021·Nursing Research·James ChircopYasuhiro Kotera

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.